

# Non Alcoholic Fatty Liver Disease (NAFLD) - Market Insight, Epidemiology and Market Forecast - 2028

<https://marketpublishers.com/r/NA1E946C15FEN.html>

Date: January 2019

Pages: 100

Price: US\$ 6,250.00 (Single User License)

ID: NA1E946C15FEN

## Abstracts

This report can be delivered to the clients within 7-10 Business Days

DelveInsight's 'Non Alcoholic Fatty Liver Disease (NAFLD) - Market Insight, Epidemiology and Market Forecast - 2028' report provides a detailed analysis of the Non Alcoholic Fatty Liver Disease (NAFLD) epidemiology and market outlook for the 7MM.

## MARKETS COVERED

United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2016-2028

Non Alcoholic Fatty Liver Disease (NAFLD) Understanding and Treatment Algorithm

The market report provides the overview of the Non Alcoholic Fatty Liver Disease (NAFLD) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Non Alcoholic Fatty Liver Disease (NAFLD) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Non Alcoholic Fatty Liver Disease (NAFLD) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

#### Non Alcoholic Fatty Liver Disease (NAFLD) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

#### Non Alcoholic Fatty Liver Disease (NAFLD) Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Non Alcoholic Fatty Liver Disease (NAFLD) market.

#### Non Alcoholic Fatty Liver Disease (NAFLD) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

#### Non Alcoholic Fatty Liver Disease (NAFLD) Report Insights

Patient Population in Non Alcoholic Fatty Liver Disease (NAFLD)

Therapeutic Approaches in Non Alcoholic Fatty Liver Disease (NAFLD)

Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Analysis

Non Alcoholic Fatty Liver Disease (NAFLD) Market Size and Trends

Non Alcoholic Fatty Liver Disease (NAFLD) Market Opportunities

Impact of upcoming Therapies in Non Alcoholic Fatty Liver Disease (NAFLD)

Non Alcoholic Fatty Liver Disease (NAFLD) Report Key Strengths

10 Year Forecast

7MM Coverage

Epidemiology Segmentation

Drugs Uptake

Highly Analyzed Market

Key Cross Competition

Non Alcoholic Fatty Liver Disease (NAFLD) Report Assessment

Current Treatment Practices in Non Alcoholic Fatty Liver Disease (NAFLD)

Unmet Needs in Non Alcoholic Fatty Liver Disease (NAFLD)

Market Attractiveness

Market Drivers and Barriers

## **KEY BENEFITS**

The report will help to develop Business Strategies by understanding the trends

shaping and driving the Non Alcoholic Fatty Liver Disease (NAFLD) market

Organize sales and marketing efforts by identifying the best opportunities for Non Alcoholic Fatty Liver Disease (NAFLD) market

To understand the future market competition in the Non Alcoholic Fatty Liver Disease (NAFLD) market.

## Contents

### **1. REPORT INTRODUCTION**

### **2. NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) MARKET OVERVIEW AT A GLANCE**

2.1. Market Share Distribution of Non Alcoholic Fatty Liver Disease (NAFLD) in 2016

2.2. Market Share Distribution of Non Alcoholic Fatty Liver Disease (NAFLD) in 2028

### **3. DISEASE BACKGROUND AND OVERVIEW: NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD)**

3.1. Introduction

3.2. Symptoms

3.3. Etiology

3.4. Risk Factors

3.5. Pathophysiology

3.6. Diagnosis

3.7. Treatment

### **4. EPIDEMIOLOGY AND PATIENT POPULATION**

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Non Alcoholic Fatty Liver Disease (NAFLD) in 7MM

4.3. Total Prevalent Patient Population of Non Alcoholic Fatty Liver Disease (NAFLD) in 7MM – By Countries

### **5. EPIDEMIOLOGY OF NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) BY COUNTRIES**

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

5.1.3. Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

5.1.4. Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

5.1.5. Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

5.1.6. Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

## 5.2. EU5

### 5.3. Assumptions and Rationale

### 5.4. Germany

#### 5.4.1. Assumptions and Rationale

#### 5.4.2. Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.4.3. Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.4.4. Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.4.5. Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.4.6. Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

### 5.5. France

#### 5.5.1. Assumptions and Rationale

#### 5.5.2. Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.5.3. Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.5.4. Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.5.5. Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.5.6. Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

### 5.6. Italy

#### 5.6.1. Assumptions and Rationale

#### 5.6.2. Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.6.3. Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.6.4. Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.6.5. Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.6.6. Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

### 5.7. Spain

#### 5.7.1. Assumptions and Rationale

#### 5.7.2. Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.7.3. Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.7.4. Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.7.5. Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.7.6. Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

### 5.8. United Kingdom

#### 5.8.1. Assumptions and Rationale

#### 5.8.2. Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.8.3. Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.8.4. Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.8.5. Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

#### 5.8.6. Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

### 5.9. Japan

#### 5.9.1. Assumptions and Rationale

- 5.9.2. Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)
- 5.9.3. Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD)
- 5.9.4. Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)
- 5.9.5. Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)
- 5.9.6. Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

## **6. CURRENT TREATMENT & MEDICAL PRACTICES**

- 6.1. Treatment Algorithm
- 6.2. Treatment Guidelines

## **7. UNMET NEEDS OF THE NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD)**

## **8. MARKETED THERAPIES**

- 8.1. Drug A: Company
  - 8.1.1. Drug Description
  - 8.1.2. Mechanism of Action
  - 8.1.3. Regulatory Milestones
  - 8.1.4. Advantages & Disadvantages
  - 8.1.5. Product Profile
- 8.2. Drug B: Company
  - 8.2.1. Drug Description
  - 8.2.2. Mechanism of Action
  - 8.2.3. Regulatory Milestones
  - 8.2.4. Advantages & Disadvantages
  - 8.2.5. Product Profile

## **9. PIPELINE THERAPIES – AT A GLANCE**

## **10. KEY CROSS COMPETITION**

## **11. EMERGING THERAPIES FOR NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD)**

- 11.1. Drug C: Company
  - 11.1.1. Drug Description
  - 11.1.2. Clinical Trials Details
  - 11.1.3. Safety and Efficacy Profile

- 11.1.4. Advantages & Disadvantages
- 11.1.5. Pipeline Development Activities
- 11.1.6. Product Profile
- 11.2. Drug D: Company
  - 11.2.1. Drug Description
  - 11.2.2. Clinical Trials Details
  - 11.2.3. Safety and Efficacy Profile
  - 11.2.4. Advantages & Disadvantages
  - 11.2.5. Pipeline Development Activities
  - 11.2.6. Product Profile

## **12. NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD): 7MM MARKET ANALYSIS**

- 12.1. 7MM Market Size of Non Alcoholic Fatty Liver Disease (NAFLD)
- 12.2. 7MM Percentage Share of drugs marketed for Non Alcoholic Fatty Liver Disease (NAFLD)
- 12.3. 7MM Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Products

## **13. NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD): COUNTRY-WISE MARKET ANALYSIS**

- 13.1. United States
  - 13.1.1. Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in United States
  - 13.1.2. Percentage Share of drugs marketed for Non Alcoholic Fatty Liver Disease (NAFLD) in United States
  - 13.1.3. Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Products in United States
  - 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.2. EU-5
  - 13.2.1. Germany
    - 13.2.1.1. Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in Germany
    - 13.2.1.2. Percentage Share of drugs marketed for Non Alcoholic Fatty Liver Disease (NAFLD) in Germany
    - 13.2.1.3. Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Products in Germany
    - 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  - 13.2.2. France
    - 13.2.2.1. Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in France
    - 13.2.2.2. Percentage Share of drugs marketed for Non Alcoholic Fatty Liver Disease



(NAFLD) in France

13.2.2.3. Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Products in France

13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.3. Italy

13.2.3.1. Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in Italy

13.2.3.2. Percentage Share of drugs marketed for Non Alcoholic Fatty Liver Disease (NAFLD) in Italy

13.2.3.3. Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Products in Italy

13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.4. Spain

13.2.4.1. Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in Spain

13.2.4.2. Percentage Share of drugs marketed for Non Alcoholic Fatty Liver Disease (NAFLD) in Spain

13.2.4.3. Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Products in Spain

13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.5. United Kingdom

13.2.5.1. Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in United Kingdom

13.2.5.2. Percentage Share of drugs marketed for Non Alcoholic Fatty Liver Disease (NAFLD) in United Kingdom

13.2.5.3. Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Products in United Kingdom

13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market

13.3. Japan

13.3.1. Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in Japan

13.3.2. Percentage Share of drugs marketed for Non Alcoholic Fatty Liver Disease (NAFLD) in Japan

13.3.3. Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Products in Japan

13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

## **14. MARKET DRIVERS**

## **15. MARKET BARRIERS**

## **16. APPENDIX**

## **17. REPORT METHODOLOGY**

17.1. Sources

## **18. DELVEINSIGHT CAPABILITIES**

## **19. DISCLAIMER**

## **20. ABOUT DELVEINSIGHT**

Indication Specific

## List Of Tables

### LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in 7MM

Table 2: Total Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028)

Table 4: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028)

Table 5: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028)

Table 6: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028)

Table 7: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028)

Table 8: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028)

Table 9: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028)

Table 10: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028)

Table 11: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028)

Table 12: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028)

Table 13: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028)

Table 14: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028)

Table 15: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028)

Table 16: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028)

Table 17: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028)

Table 18: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in

Italy (2016-2028)

Table 19: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028)

Table 20: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028)

Table 21: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028)

Table 22: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028)

Table 23: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028)

Table 24: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028)

Table 25: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028)

Table 26: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028)

Table 27: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028)

Table 28: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028)

Table 29: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028)

Table 30: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028)

Table 31: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028)

Table 32: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028)

Table 33: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028)

Table 34: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028)

Table 35: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028)

Table 36: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028)

Table 37: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41: 7MM- Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028)

Table 42: 7MM- Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Table 43: 7MM- Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Table 44: United States-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028)

Table 45: United States-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Table 46: United States-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Table 47: Germany-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028)

Table 48: Germany-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Table 49: Germany-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Table 50: France-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028)

Table 51: France-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Table 52: France-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Table 53: Italy-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028)

Table 54: Italy-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Table 55: Italy-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Table 56: Spain-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028)

Table 57: Spain-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Table 58: Spain-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Table 59:UK-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028)

Table 60:UK-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Table 61:UK-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Table 62: Japan-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028)

Table 63: Japan-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Table 64: Japan-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

## List Of Figures

### LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in 7MM

Figure 2: Total Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028)

Figure 4: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028)

Figure 5: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028)

Figure 6: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028)

Figure 7: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in United States (2016-2028)

Figure 8: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028)

Figure 9: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028)

Figure 10: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028)

Figure 11: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028)

Figure 12: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Germany (2016-2028)

Figure 13: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028)

Figure 14: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028)

Figure 15: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028)

Figure 16: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028)

Figure 17: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in France (2016-2028)

Figure 18: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD)

in Italy (2016-2028)

Figure 19: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028)

Figure 20: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028)

Figure 21: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028)

Figure 22: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Italy (2016-2028)

Figure 23: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028)

Figure 24: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028)

Figure 25: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028)

Figure 26: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028)

Figure 27: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Spain (2016-2028)

Figure 28: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028)

Figure 29: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028)

Figure 30: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028)

Figure 31: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028)

Figure 32: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in UK (2016-2028)

Figure 33: Prevalent/Incident Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028)

Figure 34: Sub-Type Specific cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028)

Figure 35: Sex- Specific Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028)

Figure 36: Diagnosed Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028)

Figure 37: Treatable Cases of the Non Alcoholic Fatty Liver Disease (NAFLD) in Japan (2016-2028)



Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41: 7MM- Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028)

Figure 42: 7MM- Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Figure 43: 7MM- Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Figure 44: United States-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028)

Figure 45: United States-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Figure 46: United States-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Figure 47: Germany-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028)

Figure 48: Germany-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Figure 49: Germany-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Figure 50: France-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028)

Figure 51: France-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Figure 52: France-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Figure 53: Italy-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028)

Figure 54: Italy-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Figure 55: Italy-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Figure 56: Spain-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028)

Figure 57: Spain-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Figure 58: Spain-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Figure 59:UK-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028)

Figure 60:UK-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Figure 61:UK-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Figure 62: Japan-Market Size of Non Alcoholic Fatty Liver Disease (NAFLD) in USD MM (2016-2028)

Figure 63: Japan-Market Share Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

Figure 64: Japan-Market Sales of Non Alcoholic Fatty Liver Disease (NAFLD) by Therapies in USD MM (2016-2028)

## I would like to order

Product name: Non Alcoholic Fatty Liver Disease (NAFLD) - Market Insight, Epidemiology and Market Forecast - 2028

Product link: <https://marketpublishers.com/r/NA1E946C15FEN.html>

Price: US\$ 6,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NA1E946C15FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

